ABBVIE INC (ABBV)       163.72  -0.22 (-0.13%)

163.72  -0.22 (-0.13%)

US00287Y1091 - Common Stock - After market: 163.5 -0.22 (-0.13%)

ABBVIE INC163.72

NYSE:ABBV (12/6/2022, 7:19:22 PM)-0.22 (-0.13%)

After market: 163.5 -0.22 (-0.13%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 10-28 2022-10-28/bmo Earnings (Next) 01-31 2023-01-31
Ins Owners 0.1% Inst Owners 69.22%
Market Cap 289.54B Shares 1.77B
PE 12.06 Fwd PE 13.55
Dividend Yield 3.71% Analysts 75.63
IPO 01-02 2013-01-02

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABBV Daily chart

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. The company also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS 60064

P: 18479327900.0

CEO: Richard A. Gonzalez

Employees: 50000

Website: https://www.abbvie.com/

ABBV News

News Image13 hours ago - Seeking AlphaKRTX stock drops after CEO change (NASDAQ:KRTX)

Karuna Therapeutics (KRTX) shed ~12% on Tuesday after naming former Allergan executive Bill Meury as president, chief executive officer. Find out the reasons for the selloff.

News Image21 hours ago - The Motley FoolIs AbbVie Stock a Buy Now?

The pharmaceutical company prepared well as Humira approaches its patent cliff next year.

News Imagea day ago - AbbVieAbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation...

News Imagea day ago - Seeking AlphaABBV stock on watch as Cigna UnitedHealth give equal access to Humira rivals (NYSE:UNH)

Following a similar move by UnitedHealth (UNH), Cigna (CI) announced Monday that the health insurer will add biosimilars to Abbvie’s (ABBV) rheumatoid arthritis drug Humira. Read full story.

News Image2 days ago - AbbVieFDA Aceita Submissão de Análise Prioritária de Epcoritamabe (DuoBody®-CD3xCD20) para o Tratamento de Linfoma de Grandes Células B Recidivo/Refratário

A submissão é fundamentada pelos dados do estudo de Fase I/II EPCORE™ NHL-1, que avalia a segurança e a eficácia preliminar de epicoritamabe, administrado de...

News Image2 days ago - The Motley FoolNew Investor? Buy These 2 Growth Stocks

A well-diversified portfolio is the key to investing!

ABBV Twits

Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example